Examkin

Question

Difficulty: HardRheumatology and Immunology

A 45-year-old woman is brought to the emergency department because of a severe, throbbing headache and blurred vision that began earlier today. She was diagnosed with diffuse cutaneous systemic sclerosis 8 months ago. Her symptoms include progressive skin thickening over her face, trunk, and extremities, as well as severe Raynaud phenomenon. Her only medication is omeprazole. Her temperature is 37.1°C (98.8°F), blood pressure is 224/118 mm Hg, pulse is 98/min, and respirations are 16/min. Physical examination shows taut, thickened skin over the fingers, hands, arms, and anterior chest, along with multiple telangiectasias. Funduscopic examination reveals bilateral papilledema. Laboratory studies show:

| Hemoglobin | 9.4 g/dL |
| Platelet count | 88,000/mm³ |
| Serum creatinine | 3.5 mg/dL (baseline 0.8 mg/dL) |
| Peripheral blood smear | numerous schistocytes |

Urinalysis shows 1+ protein and no red blood cell casts. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Administer oral captoprilAnswer
  2. B
    Initiate therapeutic plasma exchange
  3. C
    Administer intravenous methylprednisolone
  4. D
    Administer intravenous labetalol
  5. E
    Administer intravenous nitroprusside

Answer

Administer oral captopril
This patient has scleroderma renal crisis (SRC), a severe and life-threatening complication seen most commonly in patients with diffuse cutaneous systemic sclerosis, particularly within the first few years of disease onset. The pathogenesis involves intimal thickening and proliferation of the renal arcuate and interlobular arteries. This structural change leads to profound renal ischemia, which triggers massive release of renin and extreme activation of the renin-angiotensin-aldosterone system (RAAS). Clinically, SRC presents with acute malignant hypertension (often with hypertensive encephalopathy or papilledema), acute kidney injury, and frequently a microangiopathic hemolytic anemia (MAHA) characterized by schistocytes and thrombocytopenia. Because the entire crisis is driven by pathological renin release, angiotensin-converting enzyme (ACE) inhibitors are the specific, life-saving treatment of choice. Oral captopril is preferred over other agents due to its rapid onset and short half-life, allowing for safe and rapid dose titration. Crucially, ACE inhibitors must be initiated and up-titrated even in the presence of an acute elevation in serum creatinine, a scenario where ACE inhibitors are generally withheld in other forms of acute kidney injury.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and history.
The patient has a recent diagnosis of diffuse cutaneous systemic sclerosis and presents with malignant hypertension (papilledema), acute kidney injury, and microangiopathic hemolytic anemia.
Identifying the underlying rheumatologic condition provides the essential context for interpreting the acute end-organ failure.
2
Formulate a diagnosis based on the clinical triad.
The triad of systemic sclerosis, malignant hypertension, and acute kidney injury is the classic presentation of scleroderma renal crisis (SRC).
SRC is a life-threatening complication that requires immediate, disease-specific therapy rather than generic management.
3
Determine the pathophysiologic mechanism of the disease.
SRC is driven by intimal proliferation and narrowing of renal arterioles, leading to severe renal ischemia and subsequent massive, extreme activation of the renin-angiotensin-aldosterone system (RAAS).
Understanding the renin-driven mechanism directs the clinician toward the correct class of pharmacotherapy.
4
Select the most appropriate initial pharmacological intervention.
An ACE inhibitor, specifically short-acting oral captopril, is the treatment of choice to rapidly reverse the RAAS activation. It must be initiated immediately, even when the serum creatinine is significantly elevated.
ACE inhibitors are the only class of medications proven to improve mortality and long-term renal outcomes in SRC.

Key Concept

Scleroderma renal crisis presents with acute malignant hypertension and acute kidney injury in a patient with diffuse cutaneous systemic sclerosis. The cornerstone of treatment is the immediate initiation of an ACE inhibitor (e.g., captopril) to reverse extreme RAAS activation, despite the presence of acute kidney injury.
Estimated Time:1m 30s
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic